Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published online on February 16th, 2010, and are set to be published in the March 1st issue of the American Association for Cancer Research’s journal, Cancer Research…

Related Posts:

1. Study Suggests Carbon Nanotubes can cause Mesothelioma
2. Commission Approves Carilion Clinic’s Application to Sell Center for Surgical Excellence to Fairlawn Surgery Center, LLC
3. Mesothelioma Lawsuits
4. Possible Vaccine For Mesothelioma Proven Safe
5. New Research Could Help Provide Answers To Mesothelioma, England